Literature DB >> 7317235

Immediate and sustained haemodynamic effects of prazosin during upright exercise in man.

B Silke, W G Hendry, S H Taylor.   

Abstract

To ascertain the immediate pharmacodynamic and long-term haemodynamic effects of prazosin in chronic ambulant heart failure, measurements were made during sitting, standing, and walking in 12 patients with severe ischaemic left ventricular failure before and after their first dose of prazosin (2 mg) and in six of these patients after a further 12 weeks of sustained treatment (2 mg tds). When first added to treatment with digoxin and frusemide, prazosin was followed within an hour by substantial reductions in systemic arterial, pulmonary arterial, and pulmonary venous pressures in both postures at rest and also during walking. These changes were significantly attenuated after continued treatment. Cardiac output while sitting and standing at rest was reduced in both instances but the response to exercise was unchanged. The pharmacodynamic effects of prazosin in heart failure are explicable in terms of blockade of alpha1 adrenoceptors in arterial resistance and venous capacitance vessels augmented perhaps by lessening of reflex vasoconstriction secondary to the reduction in pulmonary venous pressure. The cause of the attenuation of the acute haemodynamic effects of the drug during sustained treatment is unknown.

Entities:  

Mesh:

Substances:

Year:  1981        PMID: 7317235      PMCID: PMC482714          DOI: 10.1136/hrt.46.6.663

Source DB:  PubMed          Journal:  Br Heart J        ISSN: 0007-0769


  24 in total

1.  Effects of prazosin on forearm resistance and capacitance vessels.

Authors:  N A Awan; R R Miller; K Maxwell; D T Mason
Journal:  Clin Pharmacol Ther       Date:  1977-07       Impact factor: 6.875

2.  Vasodilator therapy--a physiologic approach to the treatment of heart failure.

Authors:  E Braunwald
Journal:  N Engl J Med       Date:  1977-08-11       Impact factor: 91.245

3.  Efficacy of ambulatory systemic vasodilator therapy with oral prazosin in chronic refractory heart failure. Concomitant relief of pulmonary congestion and elevation of pump output demonstrated by improvements in symptomatology, exercise tolerance, hemodynamics and echocardiography.

Authors:  N A Awan; R R Miller; A N DeMaria; K S Maxwell; A Neumann; D T Mason
Journal:  Circulation       Date:  1977-09       Impact factor: 29.690

4.  Sustained reduction of cardiac impedance and preload in congestive heart failure with the antihypertensive vasodilator prazosin.

Authors:  R R Miller; N A Awan; K S Maxwell; D T Mason
Journal:  N Engl J Med       Date:  1977-08-11       Impact factor: 91.245

5.  Effect of prazosin vs placebo on chronic left ventricular heart failure.

Authors:  W S Aronow; M Lurie; M Turbow; K Whittaker; S Van Camp; D Hughes
Journal:  Circulation       Date:  1979-02       Impact factor: 29.690

Review 6.  Symposium on vasodilator and inotropic therapy of heart failure. Symposium perspective.

Authors:  D T Mason
Journal:  Am J Med       Date:  1978-07       Impact factor: 4.965

7.  Phentolamine for vasodilator treatment of severe heart-failure.

Authors:  P A Majid; B Sharma; S H Taylor
Journal:  Lancet       Date:  1971-10-02       Impact factor: 79.321

8.  Comparison of effects of tolmesoxide (RX71107), diazoxide, hydrallazine, prazosin, glyceryl trinitrate and sodium nitroprusside on forearm arteries and dorsal hand veins of man.

Authors:  J G Collier; R E Lorge; B F Robinson
Journal:  Br J Clin Pharmacol       Date:  1978-01       Impact factor: 4.335

9.  Clinical pharmacology and therapeutic application of prazosin in acute and chronic refractory congestive heart failure. Balanced systemic venous and arterial dilation improving pulmonary congestion and cardiac output.

Authors:  N A Awan; R R Miller; M P Miller; K Specht; Z Vera; D T Mason
Journal:  Am J Med       Date:  1978-07       Impact factor: 4.965

Review 10.  Management of refractory congestive heart failure with prazosin.

Authors:  N A Awan; M K Evenson; K E Needham; D T Mason
Journal:  Am Heart J       Date:  1981-09       Impact factor: 4.749

View more
  4 in total

1.  Haemodynamic dose-response effects of UK-52,046 in ischaemic disease with or without impaired left ventricular function.

Authors:  B Silke; A V Zezulka; S P Verma; T C Tham; S H Taylor
Journal:  Br J Clin Pharmacol       Date:  1990-06       Impact factor: 4.335

2.  Clinical importance of the renin-angiotensin system in chronic heart failure: double blind comparison of captopril and prazosin.

Authors:  J Bayliss; M S Norell; R Canepa-Anson; C Reid; P Poole-Wilson; G Sutton
Journal:  Br Med J (Clin Res Ed)       Date:  1985-06-22

Review 3.  Prazosin update. A review of its pharmacological properties and therapeutic use in hypertension and congestive heart failure.

Authors:  W F Stanaszek; D Kellerman; R N Brogden; J A Romankiewicz
Journal:  Drugs       Date:  1983-04       Impact factor: 9.546

Review 4.  Vasodilator therapy without converting-enzyme inhibition in congestive heart failure--usefulness and limitations.

Authors:  W J Remme
Journal:  Cardiovasc Drugs Ther       Date:  1989-06       Impact factor: 3.727

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.